Payment overview · 2025
General Payments
$180.12
10 reported records · 6 companies
Healthcare provider profile · identity verified
Marcus L Simmons, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MACON, GA · NPI 1770511180
Verified facts
What the public records show
CMS Open Payments records show Marcus L Simmons, MD received $180.12 in general payments during 2025 across 10 reported records.
Novo Nordisk Inc accounted for 30.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DALIRESP as an associated drug or biological on 54 records involving 42 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Daliresp by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 219 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.01 | 30.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.28 | 19.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.40 | 18.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.05 | 11.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.29 | 11.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.09 | 8.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $180.12 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.01 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.06 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $35.28 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.40 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.40 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 181 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 219 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | DALIRESP open payments reported associated product |
CMS Open Payments — General Payments 54 supporting records · 42 recipient NPIs · example record 1206139572 |
Daliresp · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
219 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
181 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 762 | 222 |
| Amlodipine Besylate | Amlodipine Besylate | 703 | 212 |
| Levothyroxine Sodium | Levothyroxine Sodium | 523 | 136 |
| Metformin Hcl | Metformin Hcl | 507 | 165 |
| Losartan Potassium | Losartan Potassium | 445 | 128 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 390 | 108 |
| Furosemide | Furosemide | 361 | 116 |
| Metoprolol Succinate | Metoprolol Succinate | 314 | 102 |
| Gabapentin | Gabapentin | 278 | 114 |
| Omeprazole | Omeprazole | 268 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 247 | 100 |
| Pravastatin Sodium | Pravastatin Sodium | 236 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 235 | 64 |
| Ozempic | Semaglutide | 219 | 38 |
| Potassium Chloride | Potassium Chloride | 199 | 79 |
| Sertraline Hcl | Sertraline Hcl | 196 | 52 |
| Eliquis | Apixaban | 181 | 47 |
| Montelukast Sodium | Montelukast Sodium | 179 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 66 |
| Hydralazine Hcl | Hydralazine Hcl | 154 | 47 |
| Alendronate Sodium | Alendronate Sodium | 153 | 41 |
| Carvedilol | Carvedilol | 152 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 60 |
| Fluticasone Propionate | Fluticasone Propionate | 144 | 68 |
| Memantine Hcl | Memantine Hcl | 139 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 138 | 31 |
| Alprazolam | Alprazolam | 125 | 33 |
| Lisinopril | Lisinopril | 124 | 38 |
| Donepezil Hcl | Donepezil Hcl | 121 | 33 |
| Simvastatin | Simvastatin | 116 | 36 |
| Spironolactone | Spironolactone | 116 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 116 | 29 |
| Glipizide | Glipizide | 110 | 30 |
| Trazodone Hcl | Trazodone Hcl | 110 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 41 |
| Ezetimibe | Ezetimibe | 107 | 39 |
| Lorazepam | Lorazepam | 101 | 37 |
| Tramadol Hcl | Tramadol Hcl | 99 | 37 |
| Famotidine | Famotidine | 93 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 40 |
| Allopurinol | Allopurinol | 83 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 51 |
| Atenolol | Atenolol | 69 | 17 |
| Pregabalin | Pregabalin | 68 | 23 |
| Buspirone Hcl | Buspirone Hcl | 67 | 21 |
| Colestipol Hcl | Colestipol Hcl | 64 | 22 |
| Meloxicam | Meloxicam | 64 | 20 |
| Azithromycin | Azithromycin | 63 | 50 |
| Metformin Hcl Er | Metformin Hcl | 62 | 19 |
| Bupropion Xl | Bupropion Hcl | 61 | 20 |
| Mirtazapine | Mirtazapine | 61 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | 14 |
| Prednisone | Prednisone | 56 | 47 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 15 |
| Mounjaro | Tirzepatide | 54 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 14 |
| Ondansetron Odt | Ondansetron | 51 | 26 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 29 |
| Nitroglycerin | Nitroglycerin | 50 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 23 |
| Donepezil Hcl Odt | Donepezil Hcl | 49 | suppressed |
| Myrbetriq | Mirabegron | 48 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 48 | 16 |
| Fenofibrate | Fenofibrate | 45 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 37 |
| Methocarbamol | Methocarbamol | 44 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 25 |
| Klor-Con M20 | Potassium Chloride | 43 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | 19 |
| Celecoxib | Celecoxib | 41 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 40 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 16 |
| Telmisartan | Telmisartan | 39 | 11 |
| Benazepril Hcl | Benazepril Hcl | 37 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 36 | 17 |
| Primidone | Primidone | 36 | 11 |
| Clonidine Hcl | Clonidine Hcl | 35 | 14 |
| Ketoconazole | Ketoconazole | 35 | 11 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 16 |
| Irbesartan | Irbesartan | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Levetiracetam | Levetiracetam | 32 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | 11 |
| Temazepam | Temazepam | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | 14 |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 19 |
| Estradiol | Estradiol | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | 11 |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 25 |
| Diazepam | Diazepam | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 24 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Minoxidil | Minoxidil | 22 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Modafinil | Modafinil | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Haegarda | C1 Esterase Inhibitor | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Daliresp | Roflumilast | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 12 | suppressed |
| Nucala | Mepolizumab | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $180.12 · 10 records | Novo Nordisk Inc | AREXVY, BREZTRI, ELIQUIS, FREESTYLE LIBRE 3, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error